Dr. Mulvaney's Publications
For a more complete list of publications, visit the following publication sites: PubMed
Mulvaney, K. M. Early Clinical Success of MTA-Cooperative PRMT5 Inhibitors for the Treatment of CDKN2A/MTAP -Deleted Cancers. Cancer Discov 13, 2310–2312 (2023).
Mulvaney, KM; Blomquist, C; Acharya, N; Li, R; Ranaghan, MJ; O’Keefe, M; Rodriguez, DJ; Young, MJ; Kesar, D; Pal, D; Stokes, M; Nelson, AJ; Jain, SS; Yang, A; Mullin-Bernstein, Z; Columbus, J; Bozal, FK; Skepner, A; Raymond, D; LaRussa, S; McKinney, DC; Freyzon, Y; Baidi, Y; Porter, D; Aguirre, A; Ianari, A; McMillan, B; Sellers, WR. Molecular basis for substrate recruitment to the PRMT5 methylosome. Molecular Cell. 2021, 81(17)17, P3481-3495. PMID:34358446.
Arthur Campbell, Martin Drysdale, Robert Hilgraf, Alessandra Ianari, Patrick McCarren, David McKinney, Brian McMillan, Kathleen Mulvaney, Dale Porter, William Sellers, Ritu Singh, Florence Wagner. Co-inventor, US Patent, PCT Application Serial No. PCT/US2021/045016, filed on August 6, 2021 and entitled, "Substrate Adaptor Inhibitors of PRMT5 and Uses Thereof” (inventors listed alphabetically).
McKinney, DC; McMillan, BJ; Ranaghan, MJ; Moroco, JA; Brousseau, M; Mullin-Bernstein, Z; O’Keefe, M; McCarren, P; Mesleh, M; Mulvaney, KM; Robinson, F; Singh, R; Bajrami, B; Wagner, FF; Hilgraf, R; Drysdale, MJ; Campbell, AJ; Skepner, A; Timm, DE; Porter, D; Kaushik, VK; Sellers, WR; Ianari, A. Discovery of a First-in-Class Inhibitor of the PRMT5–Substrate Adaptor Interaction. Journal of Medicinal Chemistry. 2021, 64 (15), 11148-11168. PMID:34342224.
MULVANEY KM, Campbell A, Drysdale M, Hilgraf R, Ianari A, McCarren P, McKinney D, McMillan B, Porter D, Sellers W, Singh R, Wagner F, inventors. BROAD INSTITUTE, DANA FARBER, assignee. Substrate Adaptor Inhibitors of PRMT5 and Uses Thereof. United States PCT/US2021/045016. 2021 August.
Song S, Nguyen V, Schrank T, Mulvaney K, Walter V, Wei D, Orvis T, Desai N, Zhang J, Hayes DN, Zheng Y, Major MB, Weissman BE. Loss of SWI/SNF Chromatin Remodeling Alters NRF2 Signaling in Non-Small Cell Lung Carcinoma. Mol Cancer Res. 2020 Dec;18(12):1777-1788. doi: 10.1158/1541-7786.MCR-20-0082. Epub 2020 Aug 27. PubMed PMID: 32855269; PubMed Central PMCID: PMC7718321.
Bowman BM, Montgomery SA, Schrank TP, Simon JM, Ptacek TS, Tamir TY, Mulvaney KM, Weir SJ, Nguyen TT, Murphy RM, Makowski L, Hayes DN, Chen XL, Randell SH, Weissman BE, Major MB. A conditional mouse expressing an activating mutation in NRF2 displays hyperplasia of the upper gastrointestinal tract and decreased white adipose tissue. J Pathol. 2020 Oct;252(2):125-137. doi: 10.1002/path.5504. Epub 2020 Aug 29. PubMed PMID: 32619021; PubMed Central PMCID: PMC7511428.
Mulvaney KM, Matson JP, Siesser PF, Tamir TY, Goldfarb D, Jacobs TM, Cloer EW, Harrison JS, Vaziri C, Cook JG, Major MB. Identification and Characterization of MCM3 as a Kelch-like ECH-associated Protein 1 (KEAP1) Substrate. J Biol Chem. 2016 Nov 4;291(45):23719-23733. doi: 10.1074/jbc.M116.729418. Epub 2016 Sep 12. PubMed PMID: 27621311; PubMed Central PMCID: PMC5095425.
Tamir*, TY; Mulvaney, KM*; M. Ben Major. Dissecting the Keap1/Nrf2 pathway through proteomics. Curr. Opin. Toxicol. 2, (2017). https://doi.org/10.1016/j.cotox.2016.10.007. (*equal contribution)
Guntas G, Lewis SM, Mulvaney KM, Cloer EW, Tripathy A, Lane TR, Major MB, Kuhlman B. Engineering a genetically encoded competitive inhibitor of the KEAP1-NRF2 interaction via structure-based design and phage display. Protein Eng Des Sel. 2016 Jan;29(1):1-9. doi: 10.1093/protein/gzv055. Epub 2015 Oct 20. PubMed PMID: 26489878; PubMed Central PMCID: PMC4678006.
Cycon KA, Mulvaney K, Rimsza LM, Persky D, Murphy SP. Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma. Immunology. 2013 Oct;140(2):259-72. doi: 10.1111/imm.12136. PubMed PMID: 23789844; PubMed Central PMCID: PMC3784172.
Hast BE, Goldfarb D, Mulvaney KM, Hast MA, Siesser PF, Yan F, Hayes DN, Major MB. Proteomic analysis of ubiquitin ligase KEAP1 reveals associated proteins that inhibit NRF2 ubiquitination. Cancer Res. 2013 Apr 1;73(7):2199-210. doi: 10.1158/0008-5472.CAN-12-4400. Epub 2013 Feb 4. PubMed PMID: 23382044; PubMed Central PMCID: PMC3618590.
Bushway M, Cycon KA, Mulvaney K, Murphy SP. Coordinate loss of MHC class II expression in the diffuse large B cell lymphoma cell line OCI-Ly2 is due to a novel mutation in RFX-AP. Immunogenetics. 2010 Feb;62(2):109-16. doi: 10.1007/s00251-009-0418-3. Epub 2009 Dec 19. PubMed PMID: 20024540.
Mulvaney, KM.; Matson, J.; Siesser, P.; Tamir, TY; Goldfarb, D.; Jacobs, T.; Cloer, EW; Harrison, JS; Vaziri, C; Cook, JG; Major, MB. Identification and Characterization of MCM3 as a KEAP1 Substrate. Journal of Biological Chemistry, 2016 Nov 4;291(45):23719-23733. PMCID:PMC5095425
Hast BE, Goldfarb D*, Mulvaney KM*, Hast MA, Siesser PF, Yan F, Hayes DN, Major MB. Proteomic analysis of ubiquitin ligase KEAP1 reveals associated proteins that inhibit NRF2 ubiquitination. Cancer Research 2013 1;73(7):2199-210. (*these authors contributed equally) PMCID: PMC3618590. (*equal contribution)